Mosby's 2014 Nursing Drug Reference (184 page)

BOOK: Mosby's 2014 Nursing Drug Reference
13.08Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

fluvastatin (Rx)

(flu′vah-stay-tin)

Lescol, Lescol XL

Func. class.:
Antilipemic

Chem. class.:
HMG-CoA reductase inhibitor

Do not confuse:
fluvastatin
/FLUoxetine

ACTION:

Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis

USES:

As an adjunct for primary hypercholesterolemia (types Ia, Ib), coronary atherosclerosis in CAD; to reduce the risk for secondary prevention of coronary events in patients with CAD; as an adjunct to diet to reduce LDL, total cholesterol, apo B levels in heterozygous familial hyper-cholesterolemia (LDL-C ≥190 mg/dl) or LDL-C ≥160 mg/dl with history of premature CV disease

CONTRAINDICATIONS:

Pregnancy (X), breastfeeding, hypersensitivity, active hepatic disease

Precautions:
Previous hepatic disease, alcoholism, severe acute infections, trauma, hypotension, uncontrolled seizure disorders, severe metabolic disorders, electrolyte imbalance, myopathy, rhabdomyolysis

DOSAGE AND ROUTES
Calculator

• Adult:
PO
20-40 mg/day in
PM
initially, usual range 20-80 mg, max 80 mg; may be given in 2 doses (40 mg
AM
, 40 mg
PM
); dosage adjustments may be made at ≥4-wk intervals

Heterozygous familial
hypercholesterolemia

• Adolescent ≥1 yr postmenarche (10-16 yr):
PO
20 mg daily at bedtime, may increase q6wk, max 40 mg bid (cap) or 80 mg (ext rel)

Available forms:
Caps 20, 40 mg; ext rel tab 80 mg

Administer:

• 
Do not break, crush, or chew ext rel tabs, use at any time of day (tab), in the evening (cap)

• 
Bile acid sequestrant should be given at least 4 hr before fluvastatin

• 
Give without regard to food

• 
Store at room temperature, protected from light

SIDE EFFECTS

CNS:
Headache, dizziness, insomnia

EENT:
Lens opacities

GI:
Abdominal pain, cramps, nausea, constipation, diarrhea, dyspepsia, flatus
,
hepatic dysfunction, pancreatitis

HEMA:
Thrombocytopenia, hemolytic anemia, leukopenia

INTEG:
Rash, pruritus

MISC:
Fatigue, influenza, photosensitivity

MS:
Myalgia,
myositis, rhabdomyolysis,
arthritis, arthralgia

RESP:
Upper respiratory infection
, rhinitis, cough, pharyngitis, sinusitis, bronchitis

PHARMACOKINETICS

Peak response 3-4 wk, metabolized in liver, >98% protein bound, excreted primarily in feces, enters breast milk, half-life 1.2 hr, steady state 4-5 wk

INTERACTIONS

Increase:
effects of warfarin, digoxin, phenytoin

Increase:
myopathy—cycloSPORINE, niacin, colchicine, protease inhibitors, fibric acid derivatives

Increase:
effects of fluvastatin—alcohol, cimetidine, ranitidine, omeprazole, phenytoin

Decrease:
fluvastatin effect—cholestyramine, colestipol, separate by ≥4 hr

Drug/Herb

Increase:
adverse reactions—red yeast rice

Drug/Food

• 
Grapefruit juice: possible increased toxicity

Drug/Lab Test

Increase:
LFTs, CK

Decrease:
platelets, WBC

NURSING CONSIDERATIONS
Assess:

• 
Hypercholesterolemia:
diet history: fats, fasting lipid profile (cholesterol, LDL, HDL, TG) before and q4-6wk, then q3-6mo when stable

• 
Hepatotoxicity/pancreatitis:
monitor hepatic studies before, q12wk after dosage change, then q6mo; AST, ALT, LFTs may be increased

• 
Renal studies in patients with compromised renal system: BUN, I&O ratio, creatinine

 
Myopathy, rhabdomyolysis:
muscle pain, tenderness; obtain baseline CPK if elevated; if these occur, product should be discontinued

Evaluate:

• 
Therapeutic response: decrease in sLDL, VLDL, total cholesterol; increased HDL, decreased triglycerides, slowing of CAD

Teach patient/family:

• 
That blood work will be necessary during treatment; to take product as prescribed, that effect may take ≥4 wk

• 
To report severe GI symptoms, headache, muscle pain, weakness, tenderness

• 
That previously prescribed regimen will continue: low-cholesterol diet, exercise program, smoking cessation

• 
To report suspected pregnancy; not to use during pregnancy (X), breastfeeding

• 
To take without regard to meals; take immediate release product in the evening, separate by ≥4 hr from bile-acid product

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

fluvoxaMINE (Rx)

(flu-vox′a-meen)

Luvox CR

Func. class.:
Antidepressant SSRI (selective serotonin reuptake inhibitor)

Do not confuse:
Luvox
/Levoxyl/Lasix/Lovenox
FluvoxaMINE
/
FLUoxetine/FluPHENAZine

ACTION:

Inhibits CNS neuron uptake of serotonin but not of norepinephrine

USES:

Obsessive-compulsive disorder, social phobia

Unlabeled uses:
Depression, bulimia nervosa, panic disorder, autism, anxiety, posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD)

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (C), breastfeeding, geriatric patients, hepatic/cardiac disease, abrupt discontinuation, dehydration, ECT, hyponatremia, hypovolemia, bipolar disorder, seizure disorder

 

Black Box Warning:

Children <8 yr, suicidal ideation

DOSAGE AND ROUTES
Calculator
Obsessive-compulsive disorder (OCD)

• Adult:
PO
50 mg at bedtime, increase by 50 mg at 4-7 day intervals, max 300 mg; doses over 100 mg should be divided;
EXT REL
100 mg at bedtime, may
titrate upward by 50 mg/wk, max 300 mg/day

• Child 12-17 yr:
PO
25 mg at bedtime, increase by 25 mg/day q4-7days, max 300 mg/day; doses over 50 mg should be divided

• Child 8-11 yr:
PO
25 mg/day at bedtime, may increase q4-7days, max 200 mg/day

Social anxiety disorder

• Adult:
PO EXT REL CAP
(Luvox CR) 100 mg at bedtime initially, titrate as needed by 50 mg/wk to 100-300 mg/day;
PO
50 mg at bedtime, titrate as needed by 50 mg q4-7days to 50-300 mg/day

• Child/adolescent 12-17 yr:
PO
25 mg at bedtime, titrate by 25-50 mg q4-7days, max 300 mg/day; if total daily dose >50 mg, divide equally

Hepatic dose/geriatric

• Adult:
PO
25 mg at bedtime, may titrate upward slowly

Autism (unlabeled)

• Adult:
PO
up to 150 mg/day

Bulimia nervosa, depression (unlabeled)

• Adult:
PO
50 mg at bedtime × 4-7 days, titrate by 25-50 mg/dose q4-7days as needed

Premenstrual dysphoric disorder (unlabeled)

• Adult:
PO
50 mg/day, may titrate to 100 mg/day

Schizophrenia (unlabeled)

• Adult:
PO
100 mg daily in combination with other agents

Posttraumatic stress disorder (PTSD) (unlabeled)

• Adult:
PO
25-50 mg at bedtime × 4-7 days then titrate by 25-50 mg/dose q4-7days, range 25-300 mg/day single or divided dose × 3-12 wk

Available forms:
Tabs 25, 50, 100 mg; ext rel cap 100, 150 mg

Administer:

• 
With food, milk for GI symptoms

• 
Immediate release:
give at bedtime; doses >100 mg/day (or >50 mg/day in those aged 8-17 yr) in 2 divided doses; if doses are not equal, give larger dose at bedtime

• 
Ext rel:
give at bedtime; do not break, crush, chew ext rel product

SIDE EFFECTS

CNS:
Headache, drowsiness, dizziness, seizures
, sleep disorders, insomnia,
suicidal ideation (children/adolescents), neuroleptic malignant syndrome–like reactions,
weakness

GI:
Nausea, anorexia, constipation
,
hepatotoxicity,
vomiting, diarrhea
, dry mouth

GU:
Decreased libido
, anorgasmia

INTEG:
Rash, sweating

PHARMACOKINETICS

Crosses blood-brain barrier, 77% protein binding, metabolism by the liver, terminal half-life 15.6 hr, peak 2-8 hr

INTERACTIONS

 
Fatal reaction—MAOIs

Increase:
CNS depression—alcohol, barbiturates, benzodiazepines

Increase:
effect of—ramelteon, thioridazine; do not use together

 
Increase:
QT prolongation, death—pimozide, do not use together

Increase:
fluvoxaMINE, toxicity levels—tricyclics, cloZAPine, alosetron, tiZANidine; do not use together

Increase:
metabolism, decrease effects—smoking

Increase:
serotonin syndrome, neuroleptic malignant syndrome: SSRIs, SNRIs, serotonin-receptor agonists, atypical antipsychotics

Increase:
bleeding risk—anticoagulants, NSAIDs, salicylates, thrombolytics

• 
Avoid use with clopidogrel

Decrease:
metabolism, increase action of propranolol, diazepam, lithium, theophylline, carBAMazepine, warfarin

Drug/Herb

Increase:
CNS effect—kava, valerian

Increase:
serotonin syndrome—tryptophan, St. John’s wort; do not use together

NURSING CONSIDERATIONS
Assess:

• 
Hepatic studies: AST, ALT, bilirubin

• 
Mental status: mood, sensorium, affect,
suicidal tendencies;
increase in psychiatric symptoms: depression, panic, obsessive-compulsive symptoms

• 
Constipation; most likely in geriatric patients

 
For toxicity: nausea, vomiting, diarrhea, syncope, increased pulse, seizures

Perform/provide:

• 
Storage at room temp; do not freeze

Evaluate:

• 
Therapeutic response: decrease in depression

Teach patient/family:

• 
That therapeutic effects may take 2-3 wk

• 
To use caution when driving, performing other activities requiring alertness because drowsiness, dizziness may occur

• 
Not to use other CNS depressants, alcohol, barbiturates, benzodiazepines, St. John’s wort, kava

• 
To notify prescriber if pregnancy is suspected, planned

• 
To notify prescriber of allergic reaction

• 
To increase bulk in diet if constipation occurs, especially in geriatric patients

 

Black Box Warning:

That suicidal thoughts/behaviors may occur

• 
To stop taking MAOIs at least 14 days before starting product

TREATMENT OF OVERDOSE:

Activated charcoal, gastric lavage

Other books

Alcott, Louisa May - SSC 14 by Behind a Mask (v1.1)
The Snow Falcon by Stuart Harrison
The Flood-Tide by Cynthia Harrod-Eagles
A Merry Little Christmas by Melanie Schuster
Design for Murder by Nancy Buckingham